Tonosoft's complex and predictive method supports preparation for the potential symptoms and problems faced by patients likely to develop circulatory and respiratory problems. The measurement of the partial pressure of carbon dioxide in the digestive system to diagnose the circulatory and respiratory status of the human body is an existing solution (ballooned probe) in highly developed health care systems. The project is currently in beta.

Investment capital will be used for:
1) Marketing cost: €250,000-€300,000
2) Product development for standardised production: €350,000-€400,000
3) Distribution, sales: €600,000-€700,000

We believe this project represents an exceptional opportunity. The project owner is forecasting a return on the total investment of €1,000,000-1,500,000 within 3 to 5 years and is offering partial ownership in the company to investors.